Human TWEAK/TNFSF12 Antibody

Name: Human TWEAK/TNFSF12 Antibody
Brand: R&D Systems
SKU: AF1090-SP
Rating: 5 (1 reviews)

AF1090 3 Citations 1 Review Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
AF1090
AF1090-SP

Bulk Orders

Human TWEAK/TNFSF12 Antibody in Neutralization

2 Images

Product Details

Citations (3)

FAQs

Supplemental Products

Reviews (1)

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human TWEAK/TNFSF12 Antibody Summary

Species Reactivity

Human

Specificity

Detects human TWEAK in direct ELISAs and Western blots. In direct ELISAs, less than 5% cross-reactivity with recombinant human (rh) BAFF, rhFas Ligand, rhGITR Ligand, rhOX40 Ligand, rhTRAIL and less than 1% cross-reactivity with rhAPRIL, rhLIGHT, rhTNF-alpha, rhVEGI, and rhTRANCE is observed.

Source

Polyclonal Goat IgG

Purification

Antigen Affinity-purified

Immunogen

E. coli-derived recombinant human TWEAK
Arg93-His249
Accession # Q4ACW9

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Applications

Recommended Concentration

Sample

Western Blot

0.1 µg/mL

Recombinant Human TWEAK/TNFSF12 (Catalog # 1090-TW)

Immunocytochemistry

5-15 µg/mL

See below

Neutralization

Measured by its ability to neutralize TWEAK/TNFSF12-induced inhibition of proliferation in the HT‑29 human colon adenocarcinoma cell line. Yu, K. Y. et al. (1999) J. Biol. Chem. 274:13733; Harrop, J. A. et al. (1998) J. Biol. Chem. 273:27548The Neutralization Dose (ND₅₀) is typically 2-8 µg/mL in the presence of 1 µg/mL Recombinant Human TWEAK/TNFSF12.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Data Examples

Neutralization

View Larger

TWEAK/TNFSF12 Inhibition of Cell Proliferation and Neutralization by Human TWEAK/TNFSF12 Antibody. Recombinant Human TWEAK/TNFSF12 (Catalog # 1090-TW) inhibits proliferation in the the HT-29 human colon adenocarcinoma cell line in a dose-dependent manner (orange line). Activity elicited by Recombinant Human TWEAK/TNFSF12 (1 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human TWEAK/ TNFSF12 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1090). The ND₅₀is typically 2-8 µg/mL.

Immunocytochemistry

View Larger

TWEAK/TNFSF12 in MDA-MB-231 Human Cell Line. TWEAK/TNFSF12 was detected in immersion fixed MDA-MB-231 human breast cancer cell line using 10 µg/mL Goat Anti-Human TWEAK/TNFSF12 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1090) for 3 hours at room temperature. Cells were stained with the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red; Catalog # NL001) and counterstained with DAPI (blue). View our protocol for Fluorescent ICC Staining of Cells on Coverslips.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS.

Reconstitution Buffer Available

Reconstitution Buffer 1 (PBS)

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: TWEAK/TNFSF12

TWEAK is a type II transmembrane protein belonging to the TNF superfamily (1). It contains a short cytoplasmic domain (amino acids (aa) 1-18), the transmembrane domain (aa 19-42) and an extracellular domain (aa 43-249). The extracellular domains of human and murine TWEAK share 89% aa sequence identity. A soluble form of TWEAK is generated from the membrane-associated molecules by proteolytic cleavage after Arg 93 suggesting that TWEAK may have long-range effects. TWEAK is expressed widely in many tissues and cells. At least two receptors that bind TWEAK have been identified (2-4). Death Receptor 3 (DR3), also known as TNFRSF12, Apo-3, LARD, WSL-1, or TRAMP, is a TNF receptor superfamily member that is expressed predominantly in tissues with high lymphocyte content (2). It has been suggested that induction of cell death by TWEAK-DR3 interaction involves the activation of NF-kappa B. In cells that lack DR3, alternate pathways of TWEAK-induced cell death mediated by receptors distinct from DR3 have been suggested (5, 6). TWEAK receptor (TWEAKR, alternatively known as FN14), is a novel TNF receptor superfamily member that also binds TWEAK (3, 4). It is a mitogen-inducible gene that is expressed in fibroblasts, hepetocellular carcinomas and endothelial cells. TWEAK-TWEAKR interaction has been shown to play a role in endothelial cell growth and migration. This effect of TWEAK is not mediated by an up-regulation of VEGF (7).

References

Chicheportiche, Y. et al. (1997) J. Biol Chem. 272:32401.
Marsters, S. et al. (1998) Current Biol. 8:525.
Wiley, S.R. et al. (2001) Immunity, 15:837.
Feng, S-L.Y. et al. (2000) Am J. Path. 156:1253.
Nakayama, M. et al. (2002) J. Immunol. 168:734.
Schneider, P. et al. (1999) Eur. J. Immunol., 29:1785.
Lynch, C. et al. (1998) J. Biol. Chem. 274:8455.

Long Name

TNF-like and Weak Inducer of Apoptosis

Entrez Gene IDs

8742 (Human); 21944 (Mouse); 360548 (Rat)

Alternate Names

APO3 ligand; APO3LMGC20669; DR3LGTWEAKAPO3/DR3 ligand; MGC129581; TNF-related weak inducer of apoptosis; TNFSF12; tumor necrosis factor (ligand) superfamily, member 12; tumor necrosis factor ligand superfamily member 12; TWEAK

Product Datasheets

Product Datasheet

COA

SDS

Related Research Areas

Citations for Human TWEAK/TNFSF12 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

3 Citations: Showing 1 - 3
Filter your results:

Filter by:

TWEAK/Fn14 pathway modulates properties of a human microvascular endothelial cell model of blood brain barrier.
Authors: Stephan D, Sbai O, Wen J, Couraud P, Putterman C, Khrestchatisky M, Desplat-Jego S
J Neuroinflammation, 2013;10(0):9.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot
Potent anti-tumor killing activity of the multifunctional Treg cell line HOZOT against human tumors with diverse origins.
Authors: Inoue T, Tashiro Y, Takeuchi M
Int. J. Oncol., 2011;38(5):1299-306.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization
Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio.
Authors: Moreno JA, Dejouvencel T, Labreuche J, Smadja DM, Dussiot M, Martin-Ventura JL, Egido J, Gaussem P, Emmerich J, Michel JB, Blanco-Colio LM, Meilhac O
Arterioscler. Thromb. Vasc. Biol., 2010;30(6):1253-62.
Species: Human
Sample Types: Cell Culture Supernates
Applications: Western Blot